ReviewScandinavian journal of clinical and laboratory investigation. Supplementum2010
Biomarkers for rheumatoid arthritis: making it personal.
Review in Scandinavian journal of clinical and laboratory investigation. Supplementum, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Trial
- Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.Arthritis research & therapy · 2014Trial
- Identification of Disulfidptosis-Related Genes and Molecular Subgroups in Rheumatoid Arthritis for Diagnostic Model and Patient Stratification.Journal of inflammation research · 2025Article
- Article
- Precision medicine in rheumatoid arthritis.Best practice & research. Clinical rheumatology · 2022Review
- The Role of Natural Products in Rheumatoid Arthritis: Current Knowledge of Basic In Vitro and In Vivo Research.Antioxidants (Basel, Switzerland) · 2021Review
- Nutrition and Rheumatoid Arthritis in the 'Omics' Era.Nutrients · 2021Review
- The Progression of Hemophilic Arthropathy: The Role of Biomarkers.International journal of molecular sciences · 2020Review
- Composite contributions of cerebrospinal fluid GABAergic neurosteroids, neuropeptide Y and interleukin-6 to PTSD symptom severity in men with PTSD.Neurobiology of stress · 2020Article
- CTHRC1: A New Candidate Biomarker for Improved Rheumatoid Arthritis Diagnosis.Frontiers in immunology · 2019Article
- A Clinician's Perspective on Biomarkers.Focus (American Psychiatric Publishing) · 2018Review
- Synovial tissue research: a state-of-the-art review.Nature reviews. Rheumatology · 2017Review
- Juggling Art: Making Critical Clinical Decisions without Vital Laboratory Support in Autoimmune Rheumatic Patients in a Resource Poor Setting.Ghana medical journal · 2017Article
- Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.Arthritis research & therapy · 2015Review
- A proteomic profile of synoviocyte lesions microdissected from formalin-fixed paraffin-embedded synovial tissues of rheumatoid arthritis.Clinical proteomics · 2015Article
- Article
- Article
- Fibronectin molecular status determination useful to differentiate between rheumatoid arthritis and systemic lupus erythematosus patients.Rheumatology international · 2013Article
- Detection of inflammatory arthritis by using hyperpolarized 13C-pyruvate with MR imaging and spectroscopy.Radiology · 2011Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Effective treatment of rheumatoid arthritis (RA) has been hampered by the heterogeneity of the disease. Although early intervention can result in disease remission, it requires early diagnosis - and current diagnostic tests are not sufficiently accurate or sensitive in the early stages of RA. As a result, RA is typically diagnosed only once damage to the joints has already begun, a time at which the window for optimal treatment may have been missed. Furthermore, a significant proportion of RA patients do not respond to any given therapeutic. Research efforts are increasingly focused on discovery of biomarkers that enable early diagnosis and stratification of RA, and thus the implementation of timely, targeted therapy. Biomarkers have the potential to transform the management of RA by enabling not only early diagnosis, but also assessment and prediction of disease severity, selection of therapy, and monitoring of response to therapy. In this mini review, we discuss the development of molecular biomarkers for RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.